Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Jeong, Seung Min ^a   Hwang, Sunsook ^b   Park, Kyungsoo ^b   Yang, Seungyeon ^a   Seong, Rho Hyun ^b  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; TUMOR PROTEIN;

AUTOPHAGY; HUMAN; METABOLISM; MITOCHONDRION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; GLUTAMIC ACID; HUMANS; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MITOCHONDRIA; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS;

EID: 84982695546     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30767     Document Type: Article

References (29)

1. Hidalgo, M. Pancreatic cancer. The New England journal of medicine 362, 1605-1617, doi: 10.1056/NEJMra0901557 (2010).
2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA: a cancer journal for clinicians 60, 277-300, doi: 10.3322/caac.20073 (2010).
3. Li, D., Xie, K., Wolff, R. & Abbruzzese, J. L. Pancreatic cancer. Lancet 363, 1049-1057, doi: 10.1016/S0140-6736(04)15841-8 (2004).
4. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & Depinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes & development 20, 1218-1249, doi: 10.1101/gad.1415606 (2006).
5. Brus, C. & Saif, M. W. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP: Journal of the pancreas 11, 321-323 (2010).
6. Weinberg, F., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America 107, 8788-8793, doi: 10.1073/pnas.1003428107 (2010).
7. Tennant, D. A., Duran, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature reviews. Cancer 10, 267-277, doi: 10.1038/nrc2817 (2010).
8. Wise, D. R. & Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends in biochemical sciences 35, 427-433, doi: 10.1016/j.tibs.2010.05.003 (2010).
9. Jones, R. G. & Thompson, C. B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes & development 23, 537-548, doi: 10.1101/gad.1756509 (2009).
10. DeBerardinis, R. J., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences of the United States of America 104, 19345-19350, doi: 10.1073/pnas.0709747104 (2007).
11. Son, J., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105, doi: 10.1038/nature12040 (2013).
12. Kundu, M. & Thompson, C. B. Autophagy: basic principles and relevance to disease. Annual review of pathology 3, 427-455, doi: 10.1146/annurev.pathmechdis.2.010506.091842 (2008).
13. Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27-42, doi: 10.1016/j.cell.2007.12.018 (2008).
14. Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075, doi: 10.1038/nature06639 (2008).
15. Yang, S., et al. Pancreatic cancers require autophagy for tumor growth. Genes & development 25, 717-729, doi: 10.1101/gad.2016111 (2011).
16. Choo, A. Y., et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Molecular cell 38, 487-499, doi: 10.1016/j.molcel.2010.05.007 (2010).
17. Robinson, M. M., et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). The Biochemical journal 406, 407-414, doi: 10.1042/BJ20070039 (2007).
18. Jeong, S. M., et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer cell 23, 450-463, doi: 10.1016/j.ccr.2013.02.024 (2013).
19. Wang, J. B., et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer cell 18, 207-219, doi: 10.1016/j.ccr.2010.08.009 (2010).
20. Duran, R. V., et al. Glutaminolysis activates Rag-mTORC1 signaling. Molecular cell 47, 349-358, doi: 10.1016/j.molcel.2012.05.043 (2012).
21. Kobayashi, S. Choose Delicately and Reuse Adequately: The Newly Revealed Process of Autophagy. Biological & pharmaceutical bulletin 38, 1098-1103, doi: 10.1248/bpb.b15-00096 (2015).
22. Lorin, S., et al. Glutamate dehydrogenase contributes to leucine sensing in the regulation of autophagy. Autophagy 9, 850-860, doi: 10.4161/auto.24083 (2013).
23. Lu, S. C. Regulation of glutathione synthesis. Molecular aspects of medicine 30, 42-59, doi: 10.1016/j.mam.2008.05.005 (2009).
24. Meijer, A. J. & Codogno, P. Autophagy: regulation and role in disease. Critical reviews in clinical laboratory sciences 46, 210-240, doi: 10.1080/10408360903044068 (2009).
25. Nicklin, P., et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534, doi: 10.1016/j. cell.2008.11.044 (2009).
26. Marino, G., et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. Molecular cell 53, 710-725, doi: 10.1016/j. molcel.2014.01.016 (2014).
27. Mullen, A. R., et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell reports 7, 1679-1690, doi: 10.1016/j.celrep.2014.04.037 (2014).
28. Sui, X., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell death & disease 4, e838, doi: 10.1038/cddis.2013.350 (2013).
29. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nature reviews. Drug discovery 10, 671-684, doi: 10.1038/nrd3504 (2011).